Media

Discover how iXpressGenes is making headlines as a leader in transformative trauma care.

Download Our Media Kit Here

In the News

Dec 17, 2024

iXpressGenes Appoints John Schmitt as CEO, Announces Nationwide TAI Test Launch

iXG is proud to appoint co-founder John Schmitt as Chief Executive Officer (CEO) and announce the nationwide launch of its Trauma Autoimmune Indicator (TAI) test

Dec 17, 2024

iXpressGenes develops new high performing DNA polymerase for COVID-19 and other pathogen testing

Scientists at iXpressGenes, on the campus of HudsonAlpha Institute for Biotechnology, have engineered a new reagent, critical to pathogen detection testing.

Dec 17, 2024

iXpressGenes awarded a $1M DoD contract to develop novel antibiotics from extremophilic microbiomes

iXG has developed a rare environmental DNA library from extremophilic environmental samples, collected from hot springs, thermal vents, and permafrost.

Recently Featured On

The Nexus Connection Ep. 1

John Schmitt, co-founder of iXpressGenes, discusses their biotechnology company's simple biochemical blood test to find markers of pre-PTSD. The test aims to prevent post-traumatic stress disorder and trauma-induced disease. The company originated from Dr. Joe Ng's experience witnessing a traumatic event and recognizing the need for immunological research.

John Schmitt on PTSD Blood Test: iXpress Genes

Up Next, is retired Lieutenant Colonel, who served 20+ years as an Army Aviation and Acquisition Corp Officer, John Schmitt. He is now CEO and co-founder of iXpress Genes, which is a PTSD diagnostic test focusing on RNA biomarkers. iXpress Genes is a simple blood test that can inform clinicians of inflammation and cellular stress caused by PTSD. For more of John’s story, sit back, relax, and get your pens ready!

The Nexus Connection Ep.10

In this episode of the Nexus Connection podcast, Brian Garcia welcomes back John Schmitt, CEO of iXpressGenes, to discuss the groundbreaking advancements in trauma screening through RNA biomarkers. The conversation covers the science behind RNA biomarkers, the impact of prolonged stress on health, and the innovative stoplight method for screening that categorizes patients' health status.